CytoMed Therapeutics (GDTC) Income Statement: Revenue & Earnings

CytoMed Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions SGD

Scale:

Scroll to see more

CytoMed Therapeutics Limited income statement - Annual data in millions SGD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.07	0.51	0.36	0.11	0.06
Cost of Revenue	0.02	0.00	0.01	0.00	0.00
Gross Profit	0.05	0.50	0.36	0.11	0.05
Operating Expenses
Research & Development	1.91	1.59	1.52	1.09	1.04
Selling, General & Administrative	1.27	1.28	0.40	0.17	0.14
Operating Expenses	3.18	3.84	1.86	1.85	1.37
Operating Income	-3.13	-3.84	-1.86	-1.74	-1.32
Other Income/Expense
Interest Income	0.32	0.29	0.00	0.00	0.00
Interest Expense	0.02	0.05	0.13	-0.12	-0.11
Other Income/Expense	0.31	-0.52	-1.15	-0.21	0.00
Income
Income Before Tax	-2.52	-4.13	-3.13	-2.05	-1.94
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-2.52	-4.13	-3.13	-2.05	-1.94
Net Income - Continuous Operations	-2.52	-4.13	-3.13	-2.05	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-2.17	-3.70	-2.61	-1.41	-1.03
EBIT	-2.50	-4.08	-3.00	-1.74	-1.32
Depreciation & Amortization	0.12	0.10	0.11	0.33	0.29
Earnings Per Share
Basic EPS	-	-	-	-	-
Diluted EPS	-	-	-	-	-
Basic Shares Outstanding	11.54	10.63	10.94	6.93	5.90
Diluted Shares Outstanding	11.54	10.63	10.94	6.93	5.90